Adopting novel technologies to improve monoclonal antibody processes
Over last 20+ year there has been significant grown in monoclonal antibody drug pipeline as well as diversity of monoclonal antibody molecules.
For example, the diversity not only includes different isoforms but also bi-specific, tri-specific, multi-specific to fragments. This diversity presents significant challenges to develop and commercialize the novel drug while meeting commercial demand from the existing molecules. This presentation will illustrate approaches to overcome these challenges by implementing novel technologies such as buffer/media supplement delivery, fluid movement using single use systems to improve current plant efficiency, streamline downstream processes and new viral inactivation approach for new class of multi-specifics antibodies.
This presentation was given during BioProduction, part of CPhI, November 3, 2022.
Dr. Nandu Deorkar